The NQO1 rs1800566 polymorphism and risk of bladder cancer: Evidence from 6,169 subjects

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 12, 2012, Pages 6343-6348

  Guo, Zhan Jing ^a   Feng, Chang Long ^b  

^a Shijiazhuang Center for Disease Control and Prevention   (China)

^b Bethune Military Medical College of PLA   (China)

Author keywords

Bladder cancer; Meta analysis; NQO1; Polymorphism

Indexed keywords

NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; ASIAN; BLADDER TUMOR; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; META ANALYSIS; RISK; RISK FACTOR;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC; RISK; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84877056451     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.12.6343     Document Type: Article

References (50)

1. Anwar A, Dehn D, Siegel D, et al (2003). Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem, 278, 10368-73.
2. Asher G, Lotem J, Kama R, et al (2002). NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA, 99, 3099-104.
3. Basu S, Brown JE, Flannigan GM, et al (2004). NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C. Int J Oncol, 25, 921-7.
4. Begg CB and Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
5. Broberg K, Bjork J, Paulsson K, et al (2005). Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis, 26, 1263-71.
6. Burger M, Catto JW, Dalbagni G, et al (2012). Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 63, 234-41.
7. Chao C, Zhang ZF, Berthiller J, et al (2006). NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-87.
8. Choi JY, Lee KM, Cho SH, et al (2003). CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics, 13, 349-55.
9. Danson S, Ward TH, Butler J and Ranson M (2004). DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev, 30, 437-49.
10. DerSimonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
11. Dhaini H, Bassma H, Kobeissi L, Jabbour M (2012). CYP2E1 and NQO1 genotypes in bladder cancer - A lebanese case-control study. Eur J Cancer, 48, S277.
12. Ding R, Lin S and Chen D (2012). Association of NQO1 rs1800566 polymorphism and the risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis, 27, 885-92.
13. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
14. Ersoy Tunali N, Tiryakioglu NO (2011). Polymorphisms in the xenobiotic genes and susceptibility to bladder cancer. J Cell Mol Biol, 9, 5-13.
15. Ersoy Tunali N, Tiryakioglu NO, Cakir OO (2012). Role of xenobiotic metabolizing gene variants in bladder cancer susceptibility. Eur J Cancer, 48, S281.
16. Figueroa JD, Malats N, Garcia-Closas M, et al (2008). Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis, 29, 1955-62.
17. Gonzalez FJ (1997). The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility. Reprod Toxicol, 11, 397-412.
18. Hung RJ, Boffetta P, Brennan P, et al (2004). Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis, 25, 973-8.
19. Iskander K, Gaikwad A, Paquet M, et al (2005). Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res, 65, 2054-8.
20. Jamieson D, Wilson K, Pridgeon S, et al (2007). NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Clin Cancer Res, 13, 1584-90.
21. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
22. Lichtenstein P, Holm NV, Verkasalo PK, et al (2000). Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343, 78-85.
23. Long DJ, 2nd, Waikel RL, Wang XJ, et al (2000). NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res, 60, 5913-5.
24. Mantel N and Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
25. Martone T, Vineis P, Malaveille C, Terracini B (2000). Impact of polymorphisms in xeno(endo)biotic metabolism on pattern and frequency of p53 mutations in bladder cancer. Mutat Res, 462, 303-9.
26. Moore LE, Wiencke JK, Bates MN, et al (2004). Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett, 211, 199-207.
27. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, et al (2007). Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol, 25, 285-95.
28. Nebert DW, Roe AL, Vandale SE, et al (2002). NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med, 4, 62-70.
29. O'Brien PJ (1991). Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact, 80, 1-41.
30. Pandith AA, Khan NP, Shah ZA, et al (2011). Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population. Biochem Genet, 49, 417-26.
31. Paonessa JD, Munday CM, Mhawech-Fauceglia P, et al (2009). 5,6-Dihydrocyclopenta[c][1,2]-dithiole-3(4H)-thione is a promising cancer chemopreventive agent in the urinary bladder. Chem Biol Interact, 180, 119-26.
32. Park SJ, Zhao H, Spitz MR, et al (2003). An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res, 536, 131-7.
33. Ploeg M, Aben KK and Kiemeney LA (2009). The present and future burden of urinary bladder cancer in the world. World J Urol, 27, 289-93.
34. Ross D, Siegel D (2004). NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol, 382, 115-44.
35. Ryk C, Kumar R, Sanyal S, et al (2006). Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett, 241, 142-9.
36. Sanyal S, Festa F, Sakano S, et al (2004). Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis, 25, 729-34.
37. Sanyal S, Ryk C, De Verdier PJ, et al (2007). Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms. Scand J Urol Nephrol, 41, 182-90.
38. Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9.
39. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21.
40. Siegel D, Gustafson DL, Dehn DL, et al (2004). NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol, 65, 1238-47.
41. Terry PD, Umbach DM, Taylor JA (2005). No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev, 14, 753-4.
42. Thakkinstian A, McKay GJ, McEvoy M, et al (2011). Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol, 173, 1365-79.
43. Tsvetkov P, Reuven N, Shaul Y (2010). Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ, 17, 103-8.
44. Vineis P, Veglia F, Garte S, et al (2007). Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol, 18, 1230-42.
45. Wacholder S, Chanock S, Garcia-Closas M, et al (2004). Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst, 96, 434-42.
46. Wang YH, Lee YH, Tseng PT, et al (2008). Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol, 134, 203-9.
47. Wen H, Ding Q, Fang ZJ, et al (2009). Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai. Int Urol Nephrol, 41, 855-64.
48. Workman P (1994). Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res, 6, 461-75.
49. Yu H, Liu H, Wang LE, Wei Q (2012). A functional NQO1 609C>T polymorphism and risk of gastrointestinal cancers: a meta-analysis. PLoS One, 7, e30566.
50. Zhang Y, Wang ZT, Zhong J (2012). Meta-analysis demonstrates that the NAD(P)H: quinone oxidoreductase 1 (NQO1) gene 609 C>T polymorphism is associated with increased gastric cancer risk in Asians. Genet Mol Res, 11, 2328-37.